BACKGROUND: Chagas disease is caused by infection with Trypanosoma cruzi. In adults, treatment with benznidazole is associated with a high incidence of adverse drug reactions (ADRs). However, in infants and children, treatment with benznidazole seems associated with a lower incidence and decreased severity of ADRs, but these effects have not been clearly characterized. OBJECTIVE: We aimed to describe ADRs observed in infants and children treated with benznidazole. PATIENTS AND METHODS: We conducted a prospective cohort study of infants and children in Argentina with Chagas disease treated with benznidazole. RESULTS: A total of 107 infants and children diagnosed with asymptomatic Chagas disease (mean age: 6.9 years) were enrolled in the study. Sixty-two events (in 44 children) were considered benznidazole related. Mean ADR duration was 8.2 days. ADRs were mild (80.6%), moderate (16%), or severe (3.2%). Most (77.3%) ADRs were in children older than 7 years. Skin was the organ with the highest incidence of ADRs (21%), followed by the central nervous system (9%) and the gastrointestinal tract (8.5%). Also, the ADR rate was lower in infants and toddlers compared with older children (18% vs 53%) (P < .001). CONCLUSIONS: Treatment with benznidazole was well tolerated in children. Most ADRs were mild and did not require treatment suspension. A strong association was observed between ADR incidence and patient age, and most ADRs occurred in children older than 7 years. We believe that anxiety over potential severe ADRs in children with Chagas disease is not justified and should not be an obstacle to using benznidazole.
BACKGROUND:Chagas disease is caused by infection with Trypanosoma cruzi. In adults, treatment with benznidazole is associated with a high incidence of adverse drug reactions (ADRs). However, in infants and children, treatment with benznidazole seems associated with a lower incidence and decreased severity of ADRs, but these effects have not been clearly characterized. OBJECTIVE: We aimed to describe ADRs observed in infants and children treated with benznidazole. PATIENTS AND METHODS: We conducted a prospective cohort study of infants and children in Argentina with Chagas disease treated with benznidazole. RESULTS: A total of 107 infants and children diagnosed with asymptomatic Chagas disease (mean age: 6.9 years) were enrolled in the study. Sixty-two events (in 44 children) were considered benznidazole related. Mean ADR duration was 8.2 days. ADRs were mild (80.6%), moderate (16%), or severe (3.2%). Most (77.3%) ADRs were in children older than 7 years. Skin was the organ with the highest incidence of ADRs (21%), followed by the central nervous system (9%) and the gastrointestinal tract (8.5%). Also, the ADR rate was lower in infants and toddlers compared with older children (18% vs 53%) (P < .001). CONCLUSIONS: Treatment with benznidazole was well tolerated in children. Most ADRs were mild and did not require treatment suspension. A strong association was observed between ADR incidence and patient age, and most ADRs occurred in children older than 7 years. We believe that anxiety over potential severe ADRs in children with Chagas disease is not justified and should not be an obstacle to using benznidazole.
Authors: Jaime A Costales; Amaya Sánchez-Gómez; Luis C Silva-Aycaguer; William Cevallos; Susana Tamayo; César A Yumiseva; Jerry O Jacobson; Luiggi Martini; Caty A Carrera; Mario J Grijalva Journal: Am J Trop Med Hyg Date: 2015-02-09 Impact factor: 2.345
Authors: Virginia Balouz; María de Los Milagros Cámara; Gaspar E Cánepa; Santiago J Carmona; Romina Volcovich; Nicolás Gonzalez; Jaime Altcheh; Fernán Agüero; Carlos A Buscaglia Journal: Clin Vaccine Immunol Date: 2015-01-14
Authors: Sabine Ottilie; Gregory M Goldgof; Claudia Magalhaes Calvet; Gareth K Jennings; Greg LaMonte; Jake Schenken; Edgar Vigil; Prianka Kumar; Laura-Isobel McCall; Eduardo Soares Constantino Lopes; Felicia Gunawan; Jennifer Yang; Yo Suzuki; Jair L Siqueira-Neto; James H McKerrow; Rommie E Amaro; Larissa M Podust; Jacob D Durrant; Elizabeth A Winzeler Journal: ACS Chem Biol Date: 2016-12-23 Impact factor: 5.100
Authors: A J Berenstein; N Falk; G Moscatelli; S Moroni; N González; F Garcia-Bournissen; G Ballering; H Freilij; J Altcheh Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno Journal: Antimicrob Agents Chemother Date: 2014-08-11 Impact factor: 5.191